2057-3804

Cardio-Oncology

Springer (Biomed Central Ltd.)

View prefix report (10.1186)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 422 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact422 DOIs
2

Add abstracts to 234 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Medium impact234 DOIs
3

Deposit reference lists for 31 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact31 DOIs

DOIs for this ISSN

Showing the top 5 of 521 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Doxorubicin cardiotoxicity and target cells: a broader persp… (10.1186/s40959-016-0012-4)
Abstract ORCID License
133.36 59
2 Rationale for setting up a cardio-oncology unit: our experie… (10.1186/s40959-016-0014-2)
Abstract ORCID License
119.33 38
3 Tyrosine kinase inhibitor associated vascular toxicity in ch… (10.1186/s40959-015-0008-5)
Abstract ORCID License
112.89 31
4 Management of atrial fibrillation in patients taking targete… (10.1186/s40959-017-0021-y)
Abstract ORCID License
102.13 22
5 Targeting endothelial cell metabolism for cardio-protection… (10.1186/s40959-016-0010-6)
Abstract ORCID License
100.68 21
6 Assessment of pazopanib-related hypertension, cardiac dysfun… (10.1186/s40959-017-0024-8)
Abstract ORCID License
100.68 21
7 Cardiac safety of afatinib: a review of data from clinical t… (10.1186/s40959-015-0006-7)
Abstract ORCID License
95.91 18
8 Hypertension in cancer patients treated with anti-angiogenic… (10.1186/s40959-015-0009-4)
Abstract ORCID License
95.91 18
9 Cardiovascular co-morbidity in cancer patients: the role of… (10.1186/s40959-016-0019-x)
Abstract ORCID License
92.28 16
10 Cardiac events during treatment with proteasome inhibitor th… (10.1186/s40959-017-0023-9)
Abstract ORCID License
88.21 14
11 Upfront dexrazoxane for the reduction of anthracycline-induc… (10.1186/s40959-019-0036-7)
Abstract ORCID
85.38 50
12 Takotsubo cardiomyopathy in cancer patients (10.1186/s40959-019-0042-9)
Abstract ORCID
80.10 39
13 Breast cancer treatment-associated cardiovascular toxicity a… (10.1186/s40959-016-0011-5)
Abstract ORCID
73.86 29
14 Low dose radiation and circulatory diseases: a brief narrati… (10.1186/s40959-015-0007-6)
Abstract ORCID
69.90 24
15 Increased skeletal intermuscular fat is associated with redu… (10.1186/s40959-019-0038-5)
Abstract ORCID
68.09 22
16 An international survey of healthcare providers’ knowledge o… (10.1186/s40959-019-0049-2)
Abstract ORCID
67.12 21
17 Use of EMPAgliflozin in the prevention of CARDiotoxicity: th… (10.1186/s40959-024-00260-y)
Abstract ORCID
66.11 20
18 Effect of myocardial dysfunction in cardiac morbidity and al… (10.1186/s40959-015-0005-8)
Abstract ORCID License
63.38 6
19 Systemic and cardiac susceptibility of immune compromised mi… (10.1186/s40959-019-0037-6)
Abstract ORCID
62.76 17
20 Cardiotoxicity and cardiovascular disease risk assessment fo… (10.1186/s40959-017-0025-7)
Abstract License
61.52 16
21 Cardiac adverse events after Chimeric Antigen Receptor (CAR)… (10.1186/s40959-024-00252-y)
Abstract ORCID
61.52 16
22 Clinical outcomes after transcatheter aortic valve replaceme… (10.1186/s40959-019-0044-7)
Abstract ORCID
60.21 15
23 Crizotinib inhibits hyperpolarization-activated cyclic nucle… (10.1186/s40959-017-0020-z)
Abstract ORCID
57.31 13
24 An Invitation from the Editors of Cardio-Oncology (10.1186/s40959-015-0004-9)
Abstract ORCID License
52.42 4
25 Use of integrated imaging and serum biomarker profiles to id… (10.1186/s40959-018-0030-5)
Abstract ORCID
52.07 10
26 NT-proBNP correlates with LVEF decline in HER2-positive brea… (10.1186/s40959-019-0039-4)
Abstract ORCID
52.07 10
27 Strategies to prevent anthracycline-induced cardiotoxicity i… (10.1186/s40959-019-0054-5)
ORCID
50.63 105
28 A quality improvement approach to reducing hospital readmiss… (10.1186/s40959-019-0041-x)
Abstract ORCID
50.00 9
29 The interplay between genetic background and sexual dimorphi… (10.1186/s40959-016-0013-3)
Abstract ORCID
47.71 8
30 Incidence and outcomes of cancer treatment-related cardiomyo… (10.1186/s40959-018-0029-y)
Abstract ORCID
47.71 8
31 Dexrazoxane makes doxorubicin-induced heart failure a rare e… (10.1186/s40959-025-00323-8)
Abstract ORCID
47.71 8
32 Persistent PR segment change in malignant pericardial diseas… (10.1186/s40959-016-0015-1)
Abstract ORCID License
45.15 3
33 Exercise intensity in cancer survivors: a matter of the hear… (10.1186/s40959-017-0022-x)
Abstract ORCID License
45.15 3
34 Symptom practice guide for telephone assessment of patients… (10.1186/s40959-017-0026-6)
Abstract ORCID License
45.15 3
35 Evaluating cardioprotective strategies for anthracycline-ind… (10.1186/s40959-025-00332-7)
Abstract ORCID
45.15 7
36 5-FU induced cardiotoxicity: case series and review of the l… (10.1186/s40959-019-0048-3)
Abstract
44.09 57
37 Etiology and management of hypertension in patients with can… (10.1186/s40959-021-00101-2)
ORCID
42.47 49
38 Effects of a novel peptide Ac-SDKP in radiation-induced coro… (10.1186/s40959-018-0034-1)
Abstract ORCID
42.25 6
39 Effects of home-based exercise with telehealth guidance in l… (10.1186/s40959-024-00249-7)
Abstract ORCID
42.25 6
40 Outcomes of patients with active cancer after transcatheter… (10.1186/s40959-024-00256-8)
Abstract ORCID
42.25 6
41 Clinical and pathological characteristics of immune checkpoi… (10.1186/s40959-024-00288-0)
Abstract ORCID
42.25 6
42 Challenges in the implementation of cardio-oncology trials:… (10.1186/s40959-024-00292-4)
Abstract ORCID
42.25 6
43 Arrhythmias, conduction disorders and sudden cardiac death i… (10.1186/s40959-025-00363-0)
Abstract ORCID
42.25 6
44 Anthracycline- and HER2-induced cardiotoxicity: mechanisms,… (10.1186/s40959-025-00386-7)
Abstract ORCID
42.25 6
45 Risk of coronary events 55 Years after Thymic irradiation in… (10.1186/s40959-018-0027-0)
Abstract License
38.91 5
46 Cardiotoxicity of venetoclax in patients with acute myeloid… (10.1186/s40959-024-00275-5)
Abstract ORCID
38.91 5
47 Revolutionizing cardiac fibrosis treatment: the potential of… (10.1186/s40959-025-00367-w)
Abstract ORCID
38.91 5
48 Efficacy and cardiovascular safety of liposomal doxorubicin:… (10.1186/s40959-025-00375-w)
Abstract ORCID
38.91 5
49 Use of Sacubitril/valsartan in patients with cardio toxicity… (10.1186/s40959-020-00078-4)
ORCID
38.60 34
50 Early- and late anthracycline-induced cardiac dysfunction: e… (10.1186/s40959-020-00079-3)
ORCID
36.18 27